Zhitong Finance App News, Bailey Tianheng (688506.SH) announced that the company's partner Bristol-Myers Squibb has received a notice from the US Food and Drug Administration (“FDA”) that the BL-B01d1 co-drug project for the treatment of advanced solid tumors has obtained FDA approval. BL-B01D1 is the world's first and only dual antibody ADC targeting EGFR×HER3 to enter the clinical stage.

Zhitong Finance App News, Bailey Tianheng (688506.SH) announced that the company's partner Bristol-Myers Squibb has received a notice from the US Food and Drug Administration (“FDA”) that the BL-B01d1 co-drug project for the treatment of advanced solid tumors has obtained FDA approval. BL-B01D1 is the world's first and only dual antibody ADC targeting EGFR×HER3 to enter the clinical stage.